Showing results (321-330 of 446) with videos related to

Sort By:
Pageof 45
Nature|August 20, 2025
TCF1 and LEF1 promote B-1a cell homeostasis and regulatory functionQian Shen, Hao Wang, Jonathan A Roco, et al.
Wellcome Open Research|June 8, 2021
SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assayMichael D Buck, Enzo Z Poirier, Ana Cardoso, et al.
Cancer Cell|January 21, 2015
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addictionGatien Moriceau, Willy Hugo, Aayoung Hong, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.
The New England Journal of Medicine|September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanomaJames Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2021
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM StudyPaolo A Ascierto, Brigitte Dréno, James Larkin, et al.
The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.
Molecular Cancer Therapeutics|February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
The New England Journal of Medicine|September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Pageof 45